Side-by-side · Research reference

CrystagenvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Crystagen

Vesugen

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Not applicable — does not operate via hormone axis

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Vesugen

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Route

Subcutaneous (presumed from bioregulator class)

Subcutaneous or intramuscular

Frequency

Unknown — bioregulator protocols variable

Not specified in available literature

Duration

Unknown — chronic administration presumed in animal models

Case series report treatment courses in elderly arterial insufficiency

Half-life

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

04Side Effects & Safety

Parameter

Crystagen

Vesugen

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Vesugen

—

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Crystagen

Vesugen

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)